ResMed Stock Falls 6% on FY2027 Guidance Miss Due to Astral Ventilator Suspension

Key Facts

In a move reflecting the operational challenges within the medical device sector, ResMed shares fell 6% after the company issued fiscal 2027 revenue guidance that missed Wall Street estimates. This decline is primarily attributed to the suspension of Astral ventilator sales, a decision expected to result in a $75 million revenue hit. According to reports, this suspension will likely create a $0.15 drag on earnings per share (EPS) during the forecast period.

These pressures emerge as the company attempts to sustain core business growth despite product-related headwinds. Based on analyst data, the revised guidance assumes zero revenue from Astral products throughout fiscal 2027, representing a headwind of approximately 130 basis points to overall growth. Despite the drop, reports suggest that core EPS growth remains resilient when excluding the specific impact of the ventilator recall.

Regarding market performance, RMD stock stood at $232.45 at the close of August 24, 2026, with daily trading ranging between $228.87 and $233.23. Investors are now watching the company's ability to offset ventilator segment losses through international sleep device sales growth, particularly as the upcoming economic calendar shows no major healthcare-specific catalysts in the immediate future.